Skip to main content
. 2020 Nov 9;43(12):1376–1387. doi: 10.1002/clc.23508

FIGURE 1.

FIGURE 1

Effects of SGLT2i on cardiovascular (a) and all cause death (b), by drug. Random effects model synthesizes the effect across all studies, and the prediction interval gives the 95% range for the result of a future SGLT2i trial. Event rates (per 1000 patient years) are shown for both the SGLT2i and the placebo arms. CKD, chronic kidney disease; CVOT, cardiovascular outcome trial; HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio